Hemosol is a small biotech company that is under pressure to meet with its research and development targets. The business is anticipating the conclusion of the second period of testing of one of its products within the next year. Hemosol must obtain more capital before the business can move on to the next phase of testing.
The firm will have to rely on the investment community for financing, however, they have been struggling with developing relationships with investors. Hemosol's president has approached the executive vice-president of the Equicom Group Inc., an investor relations companies, for aid in setting a tactical plan collectively to enhance the firm's operation and reputation.
Publication Date: 04/25/2002
This is just an excerpt. This case is about Finance
Related Case Solutions & Analyses:
Quality Imaging Products (QIP)
E-Loan: The CarFinance.com Acquisition
Telewizja Wisla
Toronto-Dominion Bank — Money Monitor
NovaStar Financial: A Short Seller’s Battle
Value Partners and the Evergrande Situation
Franklin Templeton India: The Cash Holding Dilemma
The Real Value of Say-on-Pay
Piedmont University
Transatlantic Holdings, Inc. – The Belle of the Ball
